Back to Browse Journals » Vascular Health and Risk Management » Volume 7

Lipid-lowering therapy: who can benefit

Authors Lewis SJ

Published Date August 2011 Volume 2011:7 Pages 525—534

DOI http://dx.doi.org/10.2147/VHRM.S23113

Published 24 August 2011

Sandra J Lewis
Northwest Cardiovascular Institute, Portland, OR, USA

Abstract: Cardiovascular disease (CVD) is the leading cause of death in the US. Despite the decline in CVD-associated mortality rates in recent years, coronary heart disease (CHD) still causes one in every six deaths in this country. Because most CHD risk factors are modifiable (eg, smoking, hypertension, obesity, onset of type 2 diabetes, and dyslipidemia), cardiovascular risk can be reduced by timely and appropriate interventions, such as smoking cessation, diet and lifestyle changes, and lipid-modifying therapy. Dyslipidemia, manifested by elevated low-density lipoprotein cholesterol (LDL-C), is central to the development and progression of atherosclerosis, which can be silent for decades before triggering a first major cardiovascular event. Consequently, dyslipidemia has become a primary target of intervention in strategies for the prevention of cardiovascular events. The guidelines of the Adult Treatment Panel (ATP) III, updated in 2004, recommend therapeutic lifestyle changes and the use of lipid-lowering medications, such as statins, to achieve specific LDL-C goals based on a person’s global cardiovascular risk. For high-risk individuals, such as patients with CHD and diabetic patients without CHD, an LDL-C target of < 100 mg/dL is recommended, and statin therapy should be considered to help patients achieve this goal. If correctly dosed in appropriate patients, currently approved statins are generally safe and provide significant cardiovascular benefits in diverse populations, including women, the elderly, and patients with diabetes. A recent primary prevention trial also showed that statins benefit individuals traditionally not considered at high risk of CHD, such as those with no hyperlipidemia but elevated C-reactive protein. Additional evidence suggests that statins may halt or slow atherosclerotic disease progression. Recent evidence confirms the pivotal role of statins in primary and secondary prevention.

Keywords: atherosclerosis, coronary heart disease, dyslipidemia, lipid lowering, primary prevention, statin therapy

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

MRI-based identification of undifferentiated cells: looking at the two faces of Janus

Tomuleasa C, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A

International Journal of Nanomedicine 2014, 9:865-866

Published Date: 11 February 2014

Measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery

Kidess A, El Salloukh A, Dutt P, Keane PA, Tsaloumas MD, Denniston AK

Clinical Ophthalmology 2013, 7:2299-2302

Published Date: 12 December 2013

Glistenings in hydrophobic acrylic intraocular lenses do affect visual function

Beiko GHH, Grzybowski A

Clinical Ophthalmology 2013, 7:2271-2274

Published Date: 27 November 2013

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Association between vitamin D and pressure ulcers in older ambulatory adults: results of a matched case–control study

Kalava UR, Cha SS, Takahashi PY

Clinical Interventions in Aging 2011, 6:213-219

Published Date: 2 August 2011

Improving adherence with inhaler therapy in COPD

Suzanne C Lareau, Barbara P Yawn

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:401-406

Published Date: 24 November 2010

Epidemiology of respiratory syncytial virus in children ≤2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study

Vladimir Tatochenko, Vasily Uchaikin, Aleksandr Gorelov, et al

Clinical Epidemiology 2010, 2:221-227

Published Date: 22 September 2010

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009